For Courses & Training Programmes, please visit Pelican Cancer Foundation at http://www.pelicancancer.org/our-courses
 
PEER REVIEW PUBLICATIONS 2012 ONWARDS (Please see 'Published Work' on Homepage for earlier publications)
 
Evolution of Surgical Treatment for Rectal Cancer: a Review.
Dayal S, Battersby N, Cecil T.
J Gastrointest Surg. 2017 Jul;21(7):1166-1173.
 
 
Risk of Ovarian Involvement in Advanced Colorectal or Appendiceal Tumors Involving the Peritoneum.
Mehta AM, Bignell MB, Alves S, Dayal SP, Mohamed F, Cecil TD, Moran BJ.
Dis Colon Rectum. 2017 Jul;60(7):691-696
 
 
Transanal Total Mesorectal Excision: International Registry Results of the First 720 Cases.
Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, Moran B, Hanna GB, Mortensen NJ, Tekkis PP; TaTME Registry Collaborative.
Ann Surg. 2017 Jul;266(1):111-117.
 
 
Significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis.
Lord AC, D'Souza N, Pucher PH, Moran BJ, Abulafi AM, Wotherspoon A, Rasheed S, Brown G.
Eur J Cancer. 2017 Jun 23;82:92-102.
 
 
Is it time to improve colorectal cancer surveillance from 'one size fits all' to personalized care planning?
Di Fabio F, Moran B.
Colorectal Dis. 2017 Jun;19(6):525-527.
 
 
Diagnostic and therapeutic laparoscopy in assessment and management of patients with appendiceal neoplasms.
Tan GHC, Shamji T, Mehta A, Chandrakumaran K, Dayal S, Mohamed F, Carr NJ, Rowaiye B, Cecil T, Moran BJ.
Int J Hyperthermia. 2017 Jun 28:1-5.
 
 
SAGE(S) advice: application of a standardized train the trainer model for faculty involved in a Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) hands-on course.
Wyles SM, Schwarz E, Dort J, Tariq N, Cecil T, Coleman MG, Paige J, Dunkin BJ.
Surg Endosc. 2017 May;31(5):2017-2022.
 
 
Colon cancer surgery: is it what you do, or the way you do it that matters?
Mohamed F.
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):237-238.
 
 
The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
Tan GH, Novo CA, Dayal S, Chandrakumaran K, Mohamed F, Cecil T, Moran BJ.
Eur J Surg Oncol. 2017 Feb;43(2):388-394.
 
 
Mentored experience of establishing a national peritoneal malignancy programme - Experience of first 50 operative cases.
Chang KH, Kazanowski M, Staunton O, Cahill RA, Moran BJ, Shields C, Mulsow J.
Eur J Surg Oncol. 2017 Feb;43(2):395-400.
 
 
Development and external validation of a nomogram and online tool to predict bowel dysfunction following restorative rectal cancer resection: the POLARS score.
Battersby NJ, Bouliotis G, Emmertsen KJ, Juul T, Glynne-Jones R, Branagan G, Christensen P, Laurberg S, Moran BJ; UK and Danish LARS Study Groups.
Gut. 2017 Jan 23. pii: gutjnl-2016-312695
 
 
Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes.
Di Fabio F, Mehta A, Chandrakumaran K, Mohamed F, Cecil T, Moran B.
Ann Surg Oncol. 2016 Dec;23(13):4316-4321.
 
 
Reply to Haboubi and Salmo.
Dattani M, Moran BJ.
Colorectal Dis. 2016 Dec;18(12):1187.
 
 
In Reply.
Carr NJ, Cecil TD, González-Moreno S, Mohamed F, Moran BJ, Sobin LH, Sugarbaker PH.
Am J Surg Pathol. 2016 Nov;40(11):1578.
 
 
Reply to the Letter From Dr Singhal et al.
Carr NJ, Cecil TD, González-Moreno S, Mohamed F, Moran BJ, Sobin LH, Sugarbaker PH.
Am J Surg Pathol. 2016 Sep 14.
 
 
Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kyriazanos I, Kalles V, Stefanopoulos A, Spiliotis J, Mohamed F.
Surg Oncol. 2016 Sep;25(3):308-14.
 
 
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours.
Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ.
Eur J Surg Oncol. 2016 Jul;42(7):1035-41.
 
 
Objective measurement of the distal resection margin by MRI of the fresh and fixed specimen after partial mesorectal excision for rectal cancer: 5 cm is not just 5 cm and depends on when measured.
Bondeven P, Hagemann-Madsen RH, Bro L, Moran BJ, Laurberg S, Pedersen BG.
Acta Radiol. 2016 Jul;57(7):789-95
 
 
A new internet tool to report peritoneal malignancy extent. PeRitOneal MalIgnancy Stage Evaluation (PROMISE) application.
Villeneuve L, Thivolet A, Bakrin N, Mohamed F, Isaac S, Valette PJ, Glehen O, Rousset P; BIG-RENAPE and RENAPE Working Groups.
Eur J Surg Oncol. 2016 Jun;42(6):877-82.
 
 
Watch and wait after neoadjuvant therapy for rectal cancer.
Dattani M, Moran BJ.
Br J Surg. 2016 May;103(6):629-631.
 
 
Predicting the Risk of Bowel-Related Quality-of-Life Impairment After Restorative Resection for Rectal Cancer: A Multicenter Cross-Sectional Study.
Battersby NJ, Juul T, Christensen P, Janjua AZ, Branagan G, Emmertsen KJ, Norton C, Hughes R, Laurberg S, Moran BJ; United Kingdom Low Anterior Resection Syndrome Study Group.
Dis Colon Rectum. 2016 Apr;59(4):270-80.
 
 
A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Sargant N, Roy A, Simpson S, Chandrakumaran K, Alves S, Coakes J, Bell J, Knight J, Wilson P, Mohamed F, Cecil T, Moran B.
Transfus Med. 2016 Apr;26(2):118-22.
 
 
Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study.
Battersby NJ, How P, Moran B, Stelzner S, West NP, Branagan G, Strassburg J, Quirke P, Tekkis P, Pedersen BG, Gudgeon M, Heald B, Brown G; MERCURY II Study Group.
Ann Surg. 2016 Apr;263(4):751-60
 
 
Procalcitonin levels predict infectious complications and response to treatment in patients undergoing cytoreductive surgery for peritoneal malignancy.
Saeed K, Dale AP, Leung E, Cusack T, Mohamed F, Lockyer G, Arnaudov S, Wade A, Moran B, Lewis G, Dryden M, Cecil T, Cepeda JA.
Eur J Surg Oncol. 2016 Feb;42(2):234-43.
 
 
A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process.
Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S, Taflampas P, Chapman S, Moran BJ; Peritoneal Surface Oncology Group International.
Am J Surg Pathol. 2016 Jan;40(1):14-26.
 
 
Validation of the English translation of the low anterior resection syndrome score.
Juul T, Battersby NJ, Christensen P, Janjua AZ, Branagan G, Laurberg S, Emmertsen KJ, Moran B; UK LARS Study Group.
Colorectal Dis. 2015 Oct;17(10):908-16.
 
 
The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy.
Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A.
Colorectal Dis. 2015 Sep;17(9):772-8.
 
 
Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.
Di Fabio F, Aston W, Mohamed F, Chandrakumaran K, Cecil T, Moran B.
Colorectal Dis. 2015 Aug;17(8):698-703
 
 
Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking.
Riss S, Chandrakumaran K, Dayal S, Cecil TD, Mohamed F, Moran BJ.
Eur J Surg Oncol. 2015 Mar;41(3):392-5
 
 
Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ.
Eur J Surg Oncol. 2015 Mar;41(3):396-9.
 
 
Miscellaneous conditions of the peritoneal cavity--peritoneal tumors, pseudomyxoma, mesothelioma, fibroblastic reaction, cocoon, cystic lymphatic malformations, blue-bleb, and chylous ascites.
Dayal S, Ghosh D, Moran B.
Semin Pediatr Surg. 2014 Dec;23(6):363-8.
 
 
Reversal of ileostomy utilising Lone Star Retractor System™.
Glaysher MA, Moran BJ.
Tech Coloproctol. 2014 Nov;18(11):1125-6.
 
 
Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone.
Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, Verwaal VJ, Mohamed F, Mirnezami AH.
Br J Cancer. 2014 Oct 14;111(8):1500-8.
 
Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases.
Mirnezami R, Moran BJ, Harvey K, Cecil T, Chandrakumaran K, Carr N, Mohamed F, Mirnezami AH.
World J Gastroenterol. 2014 Oct 14;20(38):14018-32.
 
 
Benefits of metastasectomy for colorectal cancer.
Cecil T, Mohamed F, Moran B.
BMJ. 2014 Jun 18;348:g4033.
 
 
Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ.
Eur J Surg Oncol. 2014 May;40(5):515-20.
 
 
The English national low rectal cancer development programme: key messages and future perspectives.
Moran BJ, Holm T, Brannagan G, Chave H, Quirke P, West N, Brown G, Glynne-Jones R, Sebag-Montefiore D, Cunningham C, Janjua AZ, Battersby NJ, Crane S, McMeeking A.
Colorectal Dis. 2014 Mar;16(3):173-8.
 
 
Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study.
Taylor FG, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, Sebag-Montefiore D, Tekkis P, Brown G; Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study Study Group.
J Clin Oncol. 2014 Jan 1;32(1):34-43.
 
 
Lymph node status does not predict local recurrence in the total mesorectal excision era.
Chand M, Moran BJ, Jones RG, Heald RJ, Brown G.
Dis Colon Rectum. 2014 Jan;57(1):127-9.
 
 
Treatment of surgically resectable colorectal peritoneal metastases.
Moran BJ, Cecil TD.
Br J Surg. 2014 Jan;101(2):5-7.
 
 
Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.
Dayal S, Taflampas P, Riss S, Chandrakumaran K, Cecil TD, Mohamed F, Moran BJ.
Dis Colon Rectum. 2013 Dec;56(12):1366-72.
 
 
The use of cardiac output monitoring to guide the administration of intravenous fluid during hyperthermic intraperitoneal chemotherapy.
Thanigaimani K, Mohamed F, Cecil T, Moran BJ, Bell J.
Colorectal Dis. 2013 Dec;15(12):1537-42.
 
 
Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Riss S, Mohamed F, Dayal S, Cecil T, Stift A, Bachleitner-Hofmann T, Moran B.
Eur J Surg Oncol. 2013 Sep;39(9):931-7.
 
 
Extra-levator abdomino-perineal excision in advanced low rectal cancer surgery.
Dayal S, Moran B.
Br J Hosp Med (Lond). 2013 Jul;74(7):381-4.
 
 
LOREC: the English Low Rectal Cancer National Development Programme.
Dayal S, Moran B.
Br J Hosp Med (Lond). 2013 Jul;74(7):377-80.
 
 
Extraperitoneal resection of the right colon for locally advanced colon cancer.
Taflampas P, Moran BJ.
Colorectal Dis. 2013 Jan;15(1):e56-9.
 
 
Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience.
Bell JC, Rylah BG, Chambers RW, Peet H, Mohamed F, Moran BJ.
Ann Surg Oncol. 2012 Dec;19(13):4244-51.
 
 
A pictorial description of extralevator abdominoperineal excision for low rectal cancer.
Shihab OC, Heald RJ, Holm T, How PD, Brown G, Quirke P, Moran BJ.
Colorectal Dis. 2012 Oct;14(10):e655-60.
 
 
Precision surgery, precision terminology: the origins and meaning of ELAPE.
Moore TJ, Moran BJ.
Colorectal Dis. 2012 Oct;14(10):1173-4.